Literature DB >> 11512084

Respiratory syncytial virus infections in previously healthy working adults.

C B Hall1, C E Long, K C Schnabel.   

Abstract

During 1975-1995, a total of 2960 healthy adults, 18-60 years of age, were prospectively evaluated for respiratory virus infections. Of these subjects, 211 (7%) acquired respiratory syncytial virus (RSV) infection. The infections were symptomatic in 84% of subjects, involved only the upper respiratory tract in 74%, and included lower respiratory tract symptoms in 26%. Overall, 40% of the subjects were febrile. Lower respiratory tract signs developed in 26%. RSV illnesses were more prolonged than non-RSV respiratory illnesses. Compared with influenza, RSV infections were less frequently associated with fever and headache, but were associated significantly more often with nasal congestion, ear and sinus involvement, and productive cough. Absence from work during the acute phase of the illness resulted from 38% of RSV infections and 66% of influenza cases. The mean duration of RSV illness (9.5 days), however, was significantly longer than that of influenza (6.8 days). The occurrence of annual epidemics of RSV, the virus' potential to reinfect all age groups, and the morbidity associated with these reinfections suggest that RSV infections in working adults may result in appreciable costs for medical visits and absence from work.

Entities:  

Mesh:

Year:  2001        PMID: 11512084     DOI: 10.1086/322657

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  89 in total

Review 1.  Respiratory Syncytial Virus Infection: An Illness for All Ages.

Authors:  Edward E Walsh
Journal:  Clin Chest Med       Date:  2016-12-27       Impact factor: 2.878

2.  Protection against respiratory syncytial virus by a recombinant Newcastle disease virus vector.

Authors:  Luis Martinez-Sobrido; Negin Gitiban; Ana Fernandez-Sesma; Jerome Cros; Sara E Mertz; Nancy A Jewell; Sue Hammond; Emilio Flano; Russell K Durbin; Adolfo García-Sastre; Joan E Durbin
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

Review 3.  Viral and host factors in human respiratory syncytial virus pathogenesis.

Authors:  Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Effect of Previous Respiratory Syncytial Virus Infection on Murine Immune Responses to F and G Protein-Containing Virus-Like Particles.

Authors:  Lori McGinnes Cullen; Madelyn R Schmidt; Trudy G Morrison
Journal:  J Virol       Date:  2019-04-17       Impact factor: 5.103

5.  Respiratory syncytial virus infection in older adults: an under-recognized problem.

Authors:  Angela R Branche; Ann R Falsey
Journal:  Drugs Aging       Date:  2015-04       Impact factor: 3.923

6.  Viral shedding and immune responses to respiratory syncytial virus infection in older adults.

Authors:  Edward E Walsh; Derick R Peterson; Aja E Kalkanoglu; Frances Eun-Hyung Lee; Ann R Falsey
Journal:  J Infect Dis       Date:  2013-02-04       Impact factor: 5.226

7.  Primary human mDC1, mDC2, and pDC dendritic cells are differentially infected and activated by respiratory syncytial virus.

Authors:  Teresa R Johnson; Christina N Johnson; Kizzmekia S Corbett; Gretchen C Edwards; Barney S Graham
Journal:  PLoS One       Date:  2011-01-28       Impact factor: 3.240

8.  Respiratory tract reinfections by the new human Metapneumovirus in an immunocompromised child.

Authors:  Gilles Pelletier; Pierre Déry; Yacine Abed; Guy Boivin
Journal:  Emerg Infect Dis       Date:  2002-09       Impact factor: 6.883

9.  NGF is an essential survival factor for bronchial epithelial cells during respiratory syncytial virus infection.

Authors:  Sreekumar Othumpangat; Laura F Gibson; Lennie Samsell; Giovanni Piedimonte
Journal:  PLoS One       Date:  2009-07-31       Impact factor: 3.240

10.  Duration of shedding of respiratory syncytial virus in a community study of Kenyan children.

Authors:  Emelda A Okiro; Lisa J White; Mwanajuma Ngama; Patricia A Cane; Graham F Medley; D James Nokes
Journal:  BMC Infect Dis       Date:  2010-01-22       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.